Skip to main content
PRCT
NASDAQ Industrial Applications And Services

PROCEPT BioRobotics Posts 19% Revenue Growth in Q2, Lifts Procedure Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$17.57
Mkt Cap
$1.04B
52W Low
$16.665
52W High
$51.18
52W Position info
5.4% above low
Off High info
66% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

PRCT is trading near its 52-week low of $16.665 (5.4% above the low) on elevated volume (2.3× avg).

Summary

PROCEPT BioRobotics reported Q2 2026 revenue of $94.5 million, up 19% year-over-year, and raised its full-year procedure volume guidance. Net loss widened to $26.9 million, while the full-year revenue outlook of $390–$410 million was reiterated.


Key Events · Earnings and Guidance · PRCT

  • Q2 Revenue Beats Expectations

    Revenue of $94.5 million grew 19% year-over-year, driven by 21% U.S. procedure growth and a record 65 HYDROS system placements.

  • Procedure Guidance Raised

    Full-year 2026 U.S. procedure volume guidance increased to 54,000–56,000, up from the prior implied range, reflecting strong demand.

  • Net Loss Widens

    Net loss expanded to $26.9 million from $19.6 million in Q2 2025, as operating expenses rose 21% to $89.8 million.

  • Adjusted EBITDA Loss Improves

    Full-year adjusted EBITDA loss guidance narrowed to $35–$30 million, better than prior expectations, signaling progress toward breakeven.


Analysis · PRCT · Industrial Applications And Services

A solid quarter saw revenue climb 19% to $94.5 million, fueled by record HYDROS system placements and higher handpiece pricing. Confidence in demand is underscored by the raised full-year U.S. procedure volume guidance, now at 54,000–56,000. Yet the net loss widened to $26.9 million from $19.6 million a year ago as operating expenses grew 21%, and cash burn persists. The reiterated revenue guidance of $390–$410 million and an improved adjusted EBITDA loss outlook paint a mixed picture: growth remains intact, but profitability is still elusive. Adding a legal overhang, this earnings report arrives just one day after a securities fraud class action lawsuit was filed against the company.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRCT was trading at $17.57 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1B. The 52-week trading range was $16.67 to $51.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRCT - Latest Insights

PRCT
Nov 04, 2026, 4:50 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.06
Real-time Price: $23.66 info
Change: +$5.60 (+31%) info
Market Cap: $1.36B info
PRCT
Nov 04, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $20.11
Real-time Price: $23.66 info
Change: +$3.55 (+18%) info
Market Cap: $1.36B info
PRCT
Aug 04, 2026, 6:36 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $18.42
Real-time Price: $23.66 info
Change: +$5.24 (+28%) info
Market Cap: $1.36B info
PRCT
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $18.62
Real-time Price: $23.66 info
Change: +$5.04 (+27%) info
Market Cap: $1.36B info
PRCT
May 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $26.52
Real-time Price: $23.66 info
Change: -$2.86 (-11%) info
Market Cap: $1.36B info